Get the Stockscreener App
0.00
100.00%
-14.49
After Hours:
14.49
14.49
+
Amicus Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$14.49
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$4.55B
Revenue:
$634.21M
Net Income/Loss:
$-27.11M
P/E Ratio:
0.00
EPS:
-0.0885
Net Cash Flow:
$29.85M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$14.50
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
0.00 | 4.55B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-29-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
MSN Money - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
Glazer Capital (FOLD) reports zero holdings after falling below 5% stake - Stock Titan
MSN - MSN
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat
Amicus Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Vanguard Capital Management holds 5.20% of Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P Global BMI Index - marketscreener.com
Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
BioMarin closes $4.8bn Amicus deal to expand rare disease portfolio - MSN
Net current asset value per share of Amicus Therapeutics, Inc. – BIVA:FOLD - TradingView
Amicus Therapeutics Hits New 52-Week High at $14.50 - Markets Mojo
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from Russell 3000E Growth Index - marketscreener.com
Amicus Therapeutics (NASDAQ: FOLD) director’s shares and options cashed out in BioMarin deal - Stock Titan
Amicus Therapeutics (FOLD) director cashes out stock and options in BioMarin deal - Stock Titan
BioMarin deal pays Amicus (NASDAQ: FOLD) director $14.50 per share - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director cashes out equity in BioMarin deal - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director equity paid out at $14.50 in BioMarin deal - Stock Titan
Director at Amicus (NASDAQ: FOLD) exits stake in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays out Amicus (NASDAQ: FOLD) director - Stock Titan
BioMarin acquisition cashes out Amicus (FOLD) director’s shares and options - Stock Titan
Amicus Therapeutics (FOLD) CAO exits stock and options in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays CDO Castelli (FOLD) $14.50 per share - Stock Titan
Amicus Therapeutics (FOLD) CPO equity fully cashed out at $14.50 deal price - Stock Titan
Amicus (FOLD) chief legal officer exits equity as BioMarin buyout pays $14.50 - Stock Titan
Amicus Therapeutics (FOLD) CFO exits equity as BioMarin acquisition closes - Stock Titan
Amicus Therapeutics (FOLD) CEO disposes 1.0M shares, options in BioMarin merger - Stock Titan
BioMarin completes $4.8B acquisition of Amicus Therapeutics - Investing.com UK
Amicus Therapeutics Q3 2025 Earnings Preview - MSN
[POS AM] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) taken private in $14.50-per-share cash merger - Stock Titan
[POSASR] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
BioMarin Pharmaceutical Closes $4.8 Billion Acquisition of Amicus Therapeutics - marketscreener.com
BioMarin completes $4.8B acquisition of Amicus Therapeutics By Investing.com - Investing.com South Africa
Amicus Therapeutics withdraws Nasdaq listing | FOLD SEC FilingForm 25-NSE - Stock Titan
BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio - TipRanks
BioMarin (NASDAQ: BMRN) adds Galafold and Pombiliti in Amicus deal - Stock Titan
BioMarin Completes Acquisition of Amicus Therapeutics - PR Newswire
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) - AOL.com
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Composite Index - marketscreener.com
CIBRA Capital Increases Amicus Therapeutics Holdings – April 2026 SEC FilingNews and Statistics - IndexBox
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):